Qube Research & Technologies (QRT)
FATE icon

Qube Research & Technologies (QRT)’s Fate Therapeutics FATE Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
+578,150
New +$1.07M ﹤0.01% 2229
2024
Q4 		– Sell
-10,422
Closed -$36.5K – 3567
2024
Q3 		$36.5K Sell
10,422
-24,712
-70% -$96.2K ﹤0.01% 2905
2024
Q2 		$115K Buy
35,134
+23,824
+211% +$104K ﹤0.01% 2573
2024
Q1 		$83K Sell
11,310
-41,132
-78% -$255K ﹤0.01% 3371
2023
Q4 		$196K Sell
52,442
-335,814
-86% -$793K ﹤0.01% 2796
2023
Q3 		$823K Buy
388,256
+209,609
+117% +$694K ﹤0.01% 1819
2023
Q2 		$850K Buy
178,647
+161,873
+965% +$893K ﹤0.01% 1364
2023
Q1 		$95.6K Sell
16,774
-475,208
-97% -$2.87M ﹤0.01% 2129
2022
Q4 		$4.96M Buy
491,982
+468,892
+2,031% +$8.81M 0.03% 668
2022
Q3 		$517K Buy
+23,090
New +$667K ﹤0.01% 1453
2021
Q4 		– Sell
-12,958
Closed -$768K – 2655
2021
Q3 		$768K Sell
12,958
-9,578
-43% -$751K 0.01% 1004
2021
Q2 		$1.96M Buy
22,536
+13,182
+141% +$1.06M 0.02% 708
2021
Q1 		$771K Buy
+9,354
New +$896K 0.01% 960
2020
Q1 		– Sell
-13,648
Closed -$267K – 1286
2019
Q4 		$267K Buy
+13,648
New +$217K 0.01% 1274

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s FATE Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Fate Therapeutics (FATE) in Q2 2026: 578,150 shares worth $1.56M. The stake represents ﹤0.01% of the portfolio and ranks #2229 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in FATE as recently as Q3 2024.

Qube Research & Technologies (QRT) first reported a position in FATE in Q4 2019 and has held it in 14 quarters since. The position peaked at $4.96M in Q4 2022. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Qube Research & Technologies (QRT) held 578,150 shares of Fate Therapeutics worth $1.56M as of Q2 2026.
  • Fate Therapeutics was a new Qube Research & Technologies (QRT) position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2229 holding.
  • Qube Research & Technologies (QRT) first reported a position in Fate Therapeutics in Q4 2019 and has held it in 14 quarters since.
  • Qube Research & Technologies (QRT)'s Fate Therapeutics position peaked at $4.96M in Q4 2022.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.